NewsPortfolio News

Kuros Biosciences reports first U.S. & UK sales of MagnetOs commercial roll-out in the U.S. and Europe on track

Kuros Biosciences Logo

Kuros Biosciences (SIX: KURN) announced today it recorded the first commercial use last week of MagnetOs in the U.S., and the company expects to ramp up its commercial activities in Europe and the U.S. in the second half of 2018.

Joshua M. Ammerman, M.D. of Washington Neurosurgical Associates in Washington DC, successfully performed minimally invasive spinal fusion using MagnetOs Putty, and was satisfied with the handling and performance of MagnetOs. Dr. Ammerman is a nationally and internationally recognized expert in the application of minimally invasive surgical techniques to disorders of the brain and spine.

Prior to this, the first commercial European use of MagnetOs occurred in the UK. Mr. Stewart Tucker MBBS, FRCS (Eng), FRCS (Ortho), performed a scoliosis intervention using MagnetOs Granules at the Wellington Hospital in London. Mr Tucker is Consultant Spinal Surgeon at Great Ormond Street Hospital for Children, and his specialist interests include childhood and adult scoliosis/kyphosis, degenerative cervical and lumbar disease, spinal trauma and spinal tumors, and complex revision spinal surgery.

Joost de Bruijn, Chief Executive Officer of Kuros, said: “After reporting successful case studies with MagnetOs at last week’s State of Spine Surgery Think Tank, we are delighted to now report the first commercial usage of MagnetOs in the U.S. and Europe. We commend Dr. Ammerman and Mr. Tucker for pioneering the clinical use of MagnetOs and look forward to ramping up our commercial effort in the U.S. and selected geographies in Europe, as we continue to execute on our strategy to build a leading orthobiologics company.”